Generic Name: Budesonide
Product Name: Pulmicort Turbuhaler/Repsules
- Maintenance treatment in persistent asthma.
- Croup (acute laryngotracheobronchitis) (nebulised budesonide only).
Reduce bronchial mucosal inflammation and bronchial hyper-reactivity.
Asthma in Adults:
- MDI /DPI 100-400micrograms twice daily (once daily dosing possible up to 400micrograms lately); up to 2000 micrograms daily in severe persistent asthma.
- Neb: 0.5-1 mg twice daily.
Asthma in Children:
- MDI /DPI 50-200 micrograms twice daily; up to 1600 micrograms daily in severe persistent asthma.
- Neb: 0.25-0.5 mg twice daily (nebulisation of budesonide requires a high flow nebuliser- 8L/min).
- Neb: 2mg as a single dose (nebulisation of budesonide requires a high flow nebuliser- 8L/min).
- Limited experience but asthma control is paramount; ADEC category- B3.
- Limited experience, should be safe to use.
Common side effects
- Oropharyngeal candidiasis
- Facial skin irritation following nebulization
Uncommon side effects
- Allergic reactions including bronchospasm, rash, urticaria, and angioedema.
- Occurrence of systemic adverse effects depends on amount of systemic absorption, which is influenced by dosage, duration of treatment and delivery system used.
- Adrenal impairment: may occur with high doses.
- Bone density loss: clinical implications concerning the risk of osteoporosis and fracture are still unknown.
- Glaucoma, cataract: risk may be increased.
- Skin thinning and bruising: may occur with high doses.
- Impaired growth: inhaled corticosteroids may reduce growth velocity mainly in the first year of treatment; effect on growth of other organs (e.g. brain and lung) is not well known; poorly controlled asthma may also cause growth retardation.
For further information talk to your doctor.